We’ve rebranded some of our products, learn more ›

CODEX is now PhenoCycler
Phenoptics is now Phenolmager

Topical Application of BMS-509744, a Selective Inhibitor of Interleukin-2-inducible T cell Kinase, Ameliorates Imiquimod-induced Skin Inflammation in Mice

Authors: Otake, Sho; Otsubaki, Tomoko; Uesato, Naofumi; Ueda, Yoshifumi; Murayama, Toshihiko; Hayashi, Mikio

Online: https://www.jstage.jst.go.jp/article/bpb/advpub/0/advpub_b20-00850/_article

Issue: Biol Pharm Bull . 2021 Apr 1;44(4):528-534.


Psoriasis is an immune disorder-related inflammatory skin disease. Recent studies have suggested a contribution of T cell activation in the pathogenesis of psoriasis. Interleukin-2 (IL-2)-inducible T cell kinase (ITK) regulates T cell activation, including proliferation, and cytokine production. In this study, we investigated the effect of the topically administered selective ITK inhibitor BMS-509744 on imiquimod (IMQ)-induced psoriasis-like skin inflammation in mice. Topically administered BMS-509744 ameliorated IMQ-induced psoriasis-like skin inflammation as shown by decreased skin lesions, epidermal thickening, and cell infiltration into the dermis. These suppressive effects occurred with lower numbers of cluster of differentiation antigen-3+ (CD3+) T cells and T helper subset 17 (Th17)-related cytokine expression in IMQ-treated skin. IMQ-induced upregulation of proinflammatory cytokine expression was also inhibited by topical application of BMS-509744 in IMQ-treated skin. Our report showed for the first time that topical application of BMS-509744 ameliorated psoriasis-like skin inflammation in mice, which is likely mediated by the inhibition of T cell activation in the skin lesions.